FierceBiotech Apr 13, 2026 Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial
FierceBiotech Apr 13, 2026 AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets
FierceBiotech Apr 13, 2026 Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s Entyvio
FierceBiotech Apr 13, 2026 BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types
FierceBiotech Apr 13, 2026 Ideaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trial
FierceBiotech Apr 13, 2026 Seaport, Hemab prepare for IPO voyages to fund depression, clotting candidates
FierceBiotech Apr 13, 2026 Regeneron rides into radiopharma via $2.1B biobucks pact with Australia’s Telix
FierceBiotech Apr 13, 2026 Allogene’s off-the-shelf CAR-T erases lingering lymphoma cells in early slice of data
FierceBiotech Apr 12, 2026 GSK CEO's 'scientific courage' propels plans for medley of phase 3 trials for Hansoh-partnered ADC
FierceBiotech Apr 10, 2026 'Can it actually deliver?': Why Big Pharma is making the leap to the quantum realm
FierceBiotech Apr 10, 2026 Philips recalls Trilogy Evo ventilator software, warns of ‘under-delivery’ of therapy
FierceBiotech Apr 9, 2026 J&J launches latest version of its pulsed ablation device after nabbing CE Mark
FierceBiotech Apr 9, 2026 Judge rules that HHS must face states' lawsuit over RFK Jr.'s agency overhaul, massive layoffs